Founder and CEO, Longevity Biotech
Hybridtides: Stable Linear Peptides and Their Use in Harnessing the Adaptive Immune System to Treat Neurodegenerative Disorders
Peptides that act like small molecules are highly desirable as drug candidates for targeting larger proteins and peptide specific binding sites. Hybridtides are synthetic peptides that blend natural and non-natural amino acids to provide a unique structure that can be carefully designed to confer 1) potency 2) specificity and 3) stability. Because of these design features, Hybridtides can be turned into clinically important drug candidates. Longevity Biotech’s most salient Hybridtide application is in neurodegeneration, which continues to be regarded as one of the world’s largest health issues. Despite billions of dollars spent on R&D for these disorders and hundreds of thousands of clinical trials, disease modifying advancements have not been made for Alzheimer’s or Parkinson’s diseases, the two most prevalent neurodegenerative disorders. Only recently has research started to target the immune system, which has been long debated as a cause or an effect of neurodegeneration. Our recent work with Hybridtide LBT-3627 to modulate T cell function is shedding new light on the role of the immune system both in terms of a novel therapeutic, as well as a stratifying / diagnostic, paradigm.
Dr. Scott Shandler is a Founder and CEO of Longevity Biotech, based in Philadelphia. Prior to founding Longevity, Dr. Shandler was a venture capitalist at BioAdvance, an early stage fund where he was responsible for therapeutics, diagnostic and biomarker opportunities. Prior to BioAdvance, Dr. Shandler was a portfolio analyst for Merck Research Labs (MRK) where he developed a forecasting model and framework to guide preclinical project prioritization efforts across several therapeutic areas. Prior to Merck, Dr. Shandler was a product manager for PolyMedix, an early stage biotech company developing antimicrobial and cardiovascular therapeutics. While at PolyMedix, Dr. Shandler assisted with their successful Series A fundraising activities. Dr. Shandler also served as a consultant and subject matter expert in Accenture’s (ACN) Pharmaceutical and Medical Products group, advising leading pharmaceutical and biotechnology companies on technology and strategy matters. Earlier in his career, he worked for Inventa, a Silicon Valley startup helping craft business solutions for Fortune 500 and startup companies alike. Dr. Shandler received his Ph.D. in Biochemistry and Molecular Biophysics from the University of Pennsylvania, an MBA from The Wharton School in the Healthcare department, a Certificate of Bioinformatics from Stanford University along with a B.A. in Computer Science from Brandeis University. Dr. Shandler has published in various leading peer reviewed journals, is an inventor on multiple patents and has served as Principal Investigator on various federal and private grants.